Cardioprotective Effect of Losartan Alone or in Combination with Remote Ischemic Preconditioning on the Biochemical Changes Induced by Ischemic/Reperfusion Injury in a Mutual Prospective Study with a Clinical and Experimental Animal Arm
Journal Title: Heart Research – Open Journal - Year 2017, Vol 4, Issue 3
Abstract
Background and Aims: Losartan is an angiotensin receptor II antagonist used clinically to reduce blood pressure and treat hypertension or hypertrophic cardiomyopathy. It is also proposed to suppress cardiac injury following reperfusion. We evaluated the potential effect of Losartan alone and in combination with remote ischemic preconditioning (RIPC), an established treatment, on the biochemical changes induced by ischemic/reperfusion injury (I/R) in both humans and rabbits. Methods: Thirty consecutive patients undergoing elective percutaneous coronary intervention (PCI) were divided into three groups (10 each): group 1 (control group without any preconditioning), group 2 (patients who were maintained on losartan (50-100 mg /day) for one month before PCI), group 3 (similar to group 2 but PCI was preceded by RIPC). On the other hand, sixty adult male New Zealand white rabbits were divided into 6 groups (10 each): group I (control), group II (sham), group III (I/R as 30 min ischemia followed by 120 min reperfusion), group IV (regular losartan 20 mg/kg for 40 days orally followed by I/R), group V (I/R preceded by RIPC) and group VI (similar to groups IV but I/R was preceded by RIPC). Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), nitric oxide (NO), troponin I (cTnI), creatine kinase MB (CK-MB) and C-reactive protein (CRP) were measured in blood for all study groups. Results: Clinical and experimental parts showed that groups with RIPC combined with losartan pretreatment enhanced cardioprotective effects of RIPC against I/R injury as evidenced by significant reduction (p<0.001) in the levels of IL-6 and cTnI; also the level of NO was significantly (p<0. 0.001) increased compared with other groups. However, this effect was not significant regarding the level of TNF-α, CK-MB nor CRP. Conclusions: Pretreatment with losartan enhances the cardioprotective effects of RIPC in ischemic reperfusion injury
Authors and Affiliations
Ayman K. M. Hassan
Keywords
Related Articles
- EP ID EP557964
- DOI 10.17140/HROJ-4-142
- Views 127
- Downloads 0
Surgical Removal of Left Atrial Appendage Thrombus in a Patient with Acute Ischemic Stroke
Atrial fibrillation is a major risk factor for ischemic stroke. Left atrial appendage thrombus is responsible for the majority of cardioembolic stroke caused by atrial fibrillation. Left atrial appendage thrombus in a pa...
Saddle Thrombus seen on Transthoracic Echo: A Rare Feature in Pulmonary Embolism
The Saddle thrombus is a rare condition characterized by presence of a large thrombus which straddles the main pulmonary arterial trunk and its bifurcation leading to acute massive Pulmonary Embolism (PE). Its incidence...
Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia
Dyslipidemia alone has been considered as one of the major modifiable risk factor for cardiovascular diseases (CVD) accounting for 50% of the 1st myocardial infarction (MI) cases worldwide.1 A recent epidemiological sur...
Inhibiting the Inhibitors, PTP1B as a Therapeutic Target in Myocardial Infarction
Biological systems self-regulate through cycles of activation and inactivation, the balance of which is critical in permitting or suppressing signaling cascades and their downstream consequences. Kinase signaling pathway...
The Sequelae of Silence: Catheter Entrapment as a Preventable Morbidity Resulting from Communication Failure
Medical errors follow a well-established association with communication failure. Seemingly benign interventions such as central venous catheterization can have far reaching consequences. A 72-year-old male required reope...